ZS Pharma is a biopharmaceutical company committed to the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases. Our initial focus is on the development of ZS-9, our product candidate in Phase 3 development for the treatment of hyperkalemia, a life-threatening condition characterized by abnormally high levels of potassium in the blood.
We are advancing ZS-9 through clinical development with the goal of obtaining approval for the treatment of acute and chronic hyperkalemia, regardless of the underlying disease state. Learn more about the results from our pivotal Phase 3 clinical trial in patients with hyperkalemia here.
Keep up to date with the latest ZS Pharma News and Updates
ZS Pharma to Present Late-Breaking Abstract Data from Phase 3 Trial of ZS-9 in State of the Art and Featured Research Session Oral Presentation at European Society of Cardiology (ESC) CongressDownload PDF
ZS Pharma Announces Second Quarter 2014 Financial ResultsDownload PDF
ZS Pharma Secures $20 Million in Debt FinancingDownload PDF